About Stryker Corporation
https://www.stryker.comStryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries.
CEO
Kevin A. Lobo
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2004-05-17 | Forward | 2:1 |
| 2000-05-15 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 785
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 15
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:33.77M
Value:$12.14B
BLACKROCK INC.
Shares:26.8M
Value:$9.63B
BLACKROCK, INC.
Shares:26.73M
Value:$9.61B
Summary
Showing Top 3 of 2,895
About Stryker Corporation
https://www.stryker.comStryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $6.06B ▲ | $2.72B ▲ | $859M ▼ | 14.18% ▼ | $2.25 ▼ | $1.36B ▼ |
| Q2-2025 | $6.02B ▲ | $2.39B ▼ | $884M ▲ | 14.68% ▲ | $2.32 ▲ | $1.47B ▲ |
| Q1-2025 | $5.87B ▼ | $2.5B ▲ | $654M ▲ | 11.15% ▲ | $1.71 ▲ | $1.04B ▲ |
| Q4-2024 | $6.44B ▲ | $2.33B ▲ | $546M ▼ | 8.48% ▼ | $1.43 ▼ | $792M ▼ |
| Q3-2024 | $5.49B | $2.19B | $834M | 15.18% | $2.19 | $1.31B |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $3.34B ▲ | $47.06B ▲ | $25.27B ▲ | $21.79B ▲ |
| Q2-2025 | $2.46B ▲ | $46.33B ▲ | $25.14B ▲ | $21.19B ▲ |
| Q1-2025 | $2.41B ▼ | $46.01B ▲ | $25.08B ▲ | $20.93B ▲ |
| Q4-2024 | $4.49B ▼ | $42.97B ▼ | $22.34B ▼ | $20.63B ▲ |
| Q3-2024 | $4.68B | $43.83B | $23.68B | $20.15B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $859M ▼ | $1.54B ▲ | $-321M ▼ | $-339M ▲ | $881M ▲ | $1.35B ▲ |
| Q2-2025 | $884M ▲ | $1.11B ▲ | $-104M ▲ | $-989M ▼ | $55M ▲ | $928M ▲ |
| Q1-2025 | $654M ▲ | $250M ▼ | $-4.14B ▼ | $2.53B ▲ | $-1.33B ▼ | $127M ▼ |
| Q4-2024 | $546M ▼ | $1.93B ▲ | $-303M ▲ | $-1.79B ▼ | $-198M ▼ | $1.67B ▲ |
| Q3-2024 | $834M | $1.47B | $-2.17B | $2.65B | $1.98B | $1.3B |
Revenue by Products
| Product | Q4-2024 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 MedSurg | $4.18Bn ▲ | $3.77Bn ▼ | $3.51Bn ▼ | $3.80Bn ▲ |
 Orthopaedics | $0 ▲ | $2.25Bn ▲ | $0 ▼ | $2.25Bn ▲ |
 Orthopaedics and Spine | $0 ▲ | $0 ▲ | $2.35Bn ▲ | $0 ▼ |
Revenue by Geography
| Region | Q3-2024 | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 NonUS | $1.39Bn ▲ | $1.49Bn ▲ | $1.47Bn ▼ | $1.43Bn ▼ |
 UNITED STATES | $4.11Bn ▲ | $0 ▼ | $0 ▲ | $4.44Bn ▲ |
CEO
Kevin A. Lobo
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2004-05-17 | Forward | 2:1 |
| 2000-05-15 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 785
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 15
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:33.77M
Value:$12.14B
BLACKROCK INC.
Shares:26.8M
Value:$9.63B
BLACKROCK, INC.
Shares:26.73M
Value:$9.61B
Summary
Showing Top 3 of 2,895